Search Results
Sep 03, 2026, 09:00 ET ZEISS elevates ophthalmic workflows at ESCRS with new surgical and digital advancements
Dr. Mfazo Hove from Blue Fin Vision (UK), Dr. Jiwon Jeong from Fatima Eye Clinic (South Korea), Dr. James Myerscough from Southend University Hospital NHS Foundation Trust (UK), and Dr. Jascha Wendelstein from The Institute for Refractive and Ophthalmic Surgery (Switzerland).ZEISS recently announced
More news about: Carl Zeiss Meditec AG
Sep 03, 2026, 09:00 ET ZEISS elevates ophthalmic workflows at ESCRS with new surgical and digital advancements
Dr. Mfazo Hove from Blue Fin Vision (UK), Dr. Jiwon Jeong from Fatima Eye Clinic (South Korea), Dr. James Myerscough from Southend University Hospital NHS Foundation Trust (UK), and Dr. Jascha Wendelstein from The Institute for Refractive and Ophthalmic Surgery (Switzerland).ZEISS recently announced
More news about: Carl Zeiss Meditec AG
Aug 31, 2026, 16:30 ET NEUBERGER HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION
NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Neuberger High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock. The distribution announced today is payable on September
More news about: Neuberger Berman
Aug 28, 2026, 11:13 ET /C O R R E C C I O N -- Bridge to Life, Ltd./
final: El NICE del Reino Unido recomienda la financiación por parte del NHS de VitaSmart™ de Bridge to Life - El NICE del Reino Unido publica una guía que recomienda la financiación rutinaria por parte del NHS del sistema de perfusión oxigenada hipotérmica VitaSmart™ de Bridge to Life
More news about: Bridge to Life, Ltd.
Aug 28, 2026, 11:08 ET NICE im Vereinigten Königreich empfiehlt in neuer Leitlinie routinemäßige NHS-Finanzierung für das VitaSmart™ Hypothermic Oxygenated Perfusion System von Bridge to Life
Finanzierung von Systemen wie VitaSmart durch den NHS läutet eine neue Ära für Lebertransplantationsprogramme im Vereinigten Königreich ein", sagte Rebeca Sanabria Mateos, leitende Fachärztin für Lebertransplantationschirurgie am University Hospitals Birmingham NHS Foundation Trust. „Dank des gleichberechtigten
More news about: Bridge to Life, Ltd.
Aug 27, 2026, 19:19 ET Au Royaume-Uni, le NICE publie des recommandations préconisant le financement systématique par le NHS du système de perfusion hypothermique oxygénée VitaSmart™ de Bridge to Life
systémique par le NHS de dispositifs tels que VitaSmart marque le début d'une nouvelle ère pour les programmes de transplantation hépatique au Royaume-Uni », déclare Rebeca Sanabria Mateos, chirurgienne spécialiste de la transplantation hépatique au University Hospitals Birmingham NHS Foundation Trust.
More news about: Bridge to Life, Ltd.
Aug 27, 2026, 19:00 ET /C O R R E C T I O N -- Bridge to Life, Ltd./
countries accepting the CE mark."Routine NHS funding for systems like VitaSmart signals a new era for liver transplantation programs in the UK," said Rebeca Sanabria Mateos, Consultant Liver Transplant Surgeon at University Hospitals Birmingham NHS Foundation Trust. "Having equitable access to efficient,
More news about: Bridge to Life, Ltd.
Aug 27, 2026, 17:18 ET UK NICE Issues Guidance Recommending Routine NHS Funding for Bridge to Life's VitaSmart™ Hypothermic Oxygenated Perfusion System
accepting the CE mark. "Routine NHS funding for systems like VitaSmart signals a new era for liver transplantation programs in the UK," said Rebeca Sanabria Mateos, Consultant Liver Transplant Surgeon at University Hospitals Birmingham NHS Foundation Trust. "Having equitable access
More news about: Bridge to Life, Ltd.
Aug 27, 2026, 08:56 ET Rongtao Medical Publishes Legacy Ultrasound Cybersecurity Framework Built on FDA, CISA and OEM Evidence
ten publish an ungated per-product operating-system or support-status document), the corrected WannaCry record from the UK National Audit Office and NHS England, and a two-axis serviceability-versus-supportability decision matrix. Where this release cites data, figures are drawn from the report's 38 cited
More news about: Rongtao Medical
Aug 27, 2026, 06:30 ET Neuberger High Yield Strategies Fund Announces Increase in Leverage
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") announced today that its Board of Directors has approved a $25 million increase in the committed debt financing available under its revolving
More news about: Neuberger Berman
Aug 26, 2026, 04:33 ET World Water Week: Hydrachem warns emergency water systems are being asked to last decades, not months
disinfection and sterilisation. Operating in over 60 countries, the company partners with NGOs, governments and leading healthcare institutions, including the NHS, to combat waterborne diseases, maintain hygienic environments and produce over 10 billion litres of safe drinking water each year.The company
More news about: Hydrachem
Aug 20, 2026, 08:30 ET DCAI and Corti Launch Sovereign AI Control Layer for European Enterprises - Trifork First to Adopt as Implementation Partner
practice management systems, and life sciences organizations worldwide. Corti serves over 100 million patients annually across health systems including the NHS. The company is headquartered in Copenhagen with offices in New York and London. For more information, visit corti.ai.About DCAIThe
More news about: Corti
Aug 20, 2026, 08:18 ET DCAI and Corti Launch Sovereign AI Control Layer for European Enterprises - Trifork First to Adopt as Implementation Partner
practice management systems, and life sciences organizations worldwide. Corti serves over 100 million patients annually across health systems including the NHS. The company is headquartered in Copenhagen with offices in New York and London. For more information, visit corti.ai.About DCAIThe
More news about: Corti
Aug 10, 2026, 11:13 ET The world's simplest heatwave advice is impossible for billions, warns Hydrachem
disinfection and sterilisation. Operating in over 60 countries, the company partners with NGOs, governments and leading healthcare institutions, including the NHS, to combat waterborne diseases, maintain hygienic environments and produce over 10 billion litres of safe drinking water each year.The company
More news about: Hydrachem
Aug 07, 2026, 11:05 ET GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
round (first year) of the NHS-Galleri trial, the largest and only randomized, controlled trial of an MCED test in an intended use population. The submission is also supported by an analysis to compare performance of the version of Galleri used in the PATHFINDER 2 study and the NHS-Galleri trial to the updated
More news about: GRAIL, Inc.
Aug 05, 2026, 16:02 ET GRAIL Reports Second Quarter 2026 Financial Results
multi-cancer early detection (MCED) studies completed to date, NHS-Galleri and PATHFINDER 2, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May.Clinical utility results from the NHS-Galleri trial showed:While Galleri did
More news about: GRAIL, Inc.
Aug 04, 2026, 10:09 ET GRAL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in GRAIL, Inc. Securities Lawsuit - Contact The Gross Law Firm
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: The Gross Law Firm
Aug 04, 2026, 10:01 ET Energy-Based Aesthetic Devices Market to Hit USD 29.39 Billion by 2036 Growing at 13.2%: Market Decipher
Germany, 2026–2036United KingdomUK growth is being driven by rapid expansion of the private aesthetics clinic sector outside NHS pathways, alongside tightening regulation of non-surgical cosmetic procedures that Market Decipher expects to favor clinics investing in higher-specification,
More news about: Market Decipher
Aug 04, 2026, 08:00 ET Triquetra Health Launches BioActive Vitamin B1™--First Complete Activation System with 5-11× More Usable B1 Plus the Cofactors That Unlock It
an absolute requirement for magnesium. Without it, even premium benfotiamine cannot complete the activation pathway. According to research cited by NHS studies, magnesium deficiency has been shown to aggravate thiamine deficiency, with clinical cases documenting patients non-responsive to thiamine supplementation
More news about: Triquetra Health LLC
Aug 04, 2026, 05:35 ET GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Claims: The lawsuit contends that GRAIL and certain senior executives misled investors regarding the clinical design, progress, and efficacy of its landmark NHS-Galleri cancer screening trial. Defendants repeatedly asserted that the study was optimally structured with a three-year follow-up period to demonstrate
More news about: Hagens Berman Sobol Shapiro LLP
Aug 03, 2026, 06:13 ET Teleradiology Market Set to Reach USD 66.7 Billion by 2036, Expanding at 18.3% CAGR Amid Rising Demand for Remote Diagnostic Imaging | Future Market Insights
transparency before deployment within hospital workflows.Similarly, Sectra's public-cloud imaging implementation at Homerton Healthcare NHS Foundation Trust demonstrates the scalability of cloud-enabled diagnostic imaging. The trust delivers approximately 250,000 imaging reports annually,
More news about: Future Market Insights
Aug 03, 2026, 02:56 ET GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with SBS Law
statements to the market. Grail misled investors about the prospects of its NHS-Galleri trial in reducing Stage III-IV cancers, concealing adverse facts from the trial while describing it positively. The Company's optimism related to the NHS-Galleri study was overstated, and ignored data suggesting its three-year
More news about: Schall, Brown & Schwartz LLP
Aug 03, 2026, 01:44 ET GRAIL, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GRAL
August 4, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Grail described its NHS-Galleri trial in positive terms while concealing adverse facts about the trial's results. Based on these facts, Grail's public statements were false
More news about: DJS Law Group LLP
Aug 02, 2026, 08:43 ET GRAL Deadline: GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: THE ROSEN LAW FIRM, P. A.
Jul 31, 2026, 16:30 ET NEUBERGER HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION
NEW YORK, July 31, 2026 /PRNewswire/ -- Neuberger High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock. The distribution announced today is payable on August
More news about: Neuberger Berman